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BACKGROUND. The link between mucus plugs and airflow obstruction has not been established in chronic severe asthma, and
the role of eosinophils and their products in mucus plug formation is unknown.
METHODS. In clinical studies, we developed and applied a bronchopulmonary segment–based scoring system to quantify
mucus plugs on multidetector computed tomography (MDCT) lung scans from 146 subjects with asthma and 22 controls,
and analyzed relationships among mucus plug scores, forced expiratory volume in 1 second (FEV1), and airway eosinophils.
Additionally, we used airway mucus gel models to explore whether oxidants generated by eosinophil peroxidase (EPO) oxidize
cysteine thiol groups to promote mucus plug formation.
RESULTS. Mucus plugs occurred in at least 1 of 20 lung segments in 58% of subjects with asthma and in only 4.5% of controls,
and the plugs in subjects with asthma persisted in the same segment for years. A high mucus score (plugs in ≥ 4 segments)
occurred in 67% of subjects with asthma with FEV1 of less than 60% of predicted volume, 19% with FEV1 of 60%–80%, and
6% with FEV1 greater than 80% (P < 0.001) and was associated with marked increases in sputum eosinophils and EPO. EPO
catalyzed oxidation of thiocyanate and bromide by H2O2 to generate oxidants that crosslink cysteine thiol groups and stiffen
thiolated hydrogels.
CONCLUSION. Mucus plugs are a plausible mechanism of chronic airflow obstruction in severe asthma, and EPO-generated
oxidants may mediate mucus plug formation. We propose an approach for quantifying airway mucus plugging using MDCT
lung scans and suggest that treating mucus plugs may improve airflow in chronic severe asthma.
TRIAL REGISTRATION. Clinicaltrials.gov NCT01718197, NCT01606826, NCT01750411, NCT01761058, NCT01761630,
NCT01759186, NCT01716494, and NCT01760915.
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mide), and pseudohalides (thiocyanate)
to generate reactive oxidants that can kill
pathogens or activate airway cells, including mast cells (9). Notably, the product
of the reaction between thiocyanate and
H2O2, catalyzed by EPO, is hypothiocyanous acid (HOSCN), which is known to
target thiol groups as a cytotoxic mechanism (10). Recently, we have reported that
oxidation of cysteine thiol groups — abundant in mucin polymers — is a mechanism
of mucus gel stiffening in the lung (11), but
the possibility that EPO promotes mucus
plug formation by generating oxidants
that modify mucins is not considered in
reviews of the pathologic effects of eosinophils in the asthmatic airway (12).
We set out to examine the association
between airway mucus plugs and airflow
obstruction in chronic severe asthma and
to explore whether eosinophils and EPO
play a pathophysiologic role in the formation of these plugs. In clinical studies, we
Figure 1. Consort diagram of CT substudy. Flow chart shows the number of asthma patients who were
developed a scoring system to quantify
screened, enrolled, and included in the final analyses.
mucus plugs in multidetector computed
tomography (MDCT) scans of the lungs,
and we used this MDCT-based scoring
system to determine the relationship between mucus plugs and
Introduction
airflow obstruction in subjects with asthma in the SARP. We also
Despite the prominence of mucus plugs in the pathophysiology of
examined the relationship between measures of mucus plugs and
airflow obstruction in acute severe (fatal) asthma (1, 2), the role
measures of airway eosinophils and EPO. In bench studies, we
of mucus plugs in the pathophysiology of airflow obstruction in
explored the pathologic effects of EPO in model systems of the
chronic severe asthma is poorly understood. This limited underairway mucus gel. Specifically, we tested to determine whether
standing is a barrier to rational treatment of airflow obstruction
EPO catalyzes reactions of H2O2 with thiocyanate or bromide to
in severe asthma because mucus plugs represent a tractable
treatment target if they can be shown to be a cause of obstrucgenerate oxidants that target cysteine thiols to crosslink them or
tion. Developing an understanding of the role of mucus plugs as
that modify thiolated hydrogels to increase elasticity.
a mechanism of airflow obstruction in chronic severe asthma has
been held back by methodologic difficulties. To date, imaging
Results
studies have not systematically examined the airways in patients
Human subjects. MDCT scans of 146 adults with asthma and 22
with asthma for intraluminal mucus and studies that have docuhealthy controls in the NHLBI SARP were analyzed (Figure 1 and
mented a relationship between mucus pathology and airflow have
Supplemental Table 1; supplemental material available online
relied on chronic cough and sputum production, a symptom comwith this article; https://doi.org/10.1172/JCI95693DS1). Among
plex known as chronic mucus hypersecretion (CMH) (3, 4). Relithe 146 patients with asthma, 66% had disease qualifying as
ance on CMH symptoms to identify patients with airway mucus
severe using American Thoracic Society/European Respiratory
plugs is problematic because CMH symptoms are often absent
Society (ATS/ERS) criteria (Table 1) (13), and the prebronchodiin patients with chronic obstructive pulmonary disease who have
lator forced expiratory volume in 1 second (FEV1) was less than
pathologically proven mucus plugs (5).
80% of predicted volume in 97 patients (66%) and less than 60%
Pathology studies in small numbers of patients with nonfaof predicted volume in 39 patients (27%).
tal asthma reveal airway mucus plugs (6), but the relationship
Airway mucus plugs can be identified and quantified using
between these plugs and airflow obstruction is unclear. In addiMDCT imaging of the lungs. In preliminary studies, we discovered
tion, blood and airway eosinophilia are strongly correlated with
that we could discern mucus plugs in the lungs of subjects with
airflow obstruction in asthma (7, 8), but the relationship between
asthma using MDCT scans. Specifically, we could identify mucus
eosinophils and mucus plugs is unknown. Eosinophils secrete
plugs as areas of opacification within the airway lumen, contigmultiple biologically active molecules, including granule proteins,
uous with patent airway lumen across sequential transverse CT
lipid mediators, chemotactic peptides, and cytokines. Eosinophil
slices. These opacities were less radiodense than adjacent blood
peroxidase (EPO) is the most abundant granule protein, and it
vessels, and occlusion of the lumen by these opacities could be
utilizes respiratory burst–derived H2O2, halides (chloride and bropartial or complete. These mucus plugs were predominantly seen
998
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each subject. This approach
generated scores ranging from
0 to 20 in increments of 0.5. In
Characteristic
All
Mucus score
this way, we found that mucus
Zero
Low
High
(n = 146)
(n = 61)
(n = 45)
(n = 40)
plugging was present in at least
Mucus score
0.5 (0–4.5)
0 (0)
1.5 (0.5–2.5)
9.5 (6–12)
1 of 20 lung segments in 58%
46.8 ± 16.0
43.2 ± 15.4
46.7 ± 15.6
52.3 ± 16.3
Mean age (yr)A
(85/146) of asthmatic subjects
Female sex, no. (%)
91 (62.3)
43 (70.5)
26 (57.8)
22 (55.0)
and in only 4.5% (1/22) of
32.7 ± 9.3
34.3 ± 9.9
32.5 ± 10.5
30.7 ± 6.3
Body mass index (kg/m2)
healthy controls (Figure 2E).
Maintenance corticosteroid use, no. (%)
The intraclass correlation coefInhaled, any dose
141 (96.6)
56 (91.8)
45 (100.0)
40 (100.0)
ficient (ICC) for between-rater
102 (69.9)
36 (59.0)
30 (66.7)
36 (90.0)
Inhaled, high doseA
mucus score agreement was
15 (10.3)
3 (4.9)
3 (6.7)
9 (22.5)
SystemicA
0.80 (95% CI 0.74 to 0.85) for
18 (14–21)
19 (15–21)
18 (14–22)
16.5 (13–19)
ACTA
all 168 scans. In addition, the
A,B
96 (65.8)
31 (50.8)
29 (64.4)
36 (90.0)
Severe asthma, no. (%)
within-rater mucus score agreeSpirometry
A,C
ment for a random subset of 14
72.2 ± 20.6
81.0 ± 16.2
74.5 ± 20.8
56.1 ± 17.4
FEV1 (% of predicted volume)
A,C,D
scans (3 healthy, 11 asthma)
0.7 (0, 4.4)
0.2 (0, 0.9)
0.5 (0.2, 1.6)
7.3 (1.5, 21.4)
Sputum eosinophil count (%)
that was scored twice by each
306 ± 276
209 ± 153
309 ± 282
459 ± 349
Blood eosinophil count (×106/l)A,C,E
of the 5 radiologists was 0.99
22 (12, 33)
18 (10, 27)
24 (13, 38)
28 (19, 40)
FeNO (ppm)A,F
41 (34.0)
18 (29.5)
10 (22.2)
13 (32.5)
CMH, no. (%)G
(95% CI 0.99 to 1.00). Among
Bronchiectasis on CT, no. (%)
29 (19.9)
7 (11.5)
11 (24.4)
11 (27.5)
subjects with asthma, the median value of the mucus score in
Data reported as mean ± SD or median (IQR). Zero represents the mucus absent group (mucus score = 0). Low
the mucus-present group was
represents the group with mucus scores 0.5–3.5, and high represents the group with mucus scores of 4 or more,
based on the median score of 3.5 in the mucus present group. AP < 0.05 for comparison of zero and high scores.
3.5, and we used this value to
B
The classification of asthma severity was determined using ATS/ERS criteria. CP < 0.05 for comparison of low
divide the asthmatic subjects
and high scores. DSputum cell counts were not available in 40 subjects due to ineligibility for sputum induction or
into 3 mucus subgroups based
because the induced sputum did not meet quality metrics. EBlood measurements were not available for 2 subjects.
on mucus score. Asthmatic
F
FeNO was not measured in 4 subjects. GDefined by WHO. Questionnaire data are missing in 25 patients (see
subjects with a mucus score
Supplemental Methods).
of 0 were assigned to the zero
mucus group, while those with
mucus scores between 0.5 and
3.5 were assigned to the low
in subsegmental airways, appearing as focal or branching opacimucus group and those with mucus scores between 4 and 20 were
ties (Figure 2, A–C), and usually occurred in the absence of bronassigned to the high mucus group (Figure 2F).
chial dilatation. Based on these findings, we went on to develop a
Twenty-five asthmatic subjects in SARP 3 also had HRCT
visual scoring system to formally quantify mucus plugs in MDCT
scans performed previously as part of SARP 1 or SARP 2 (Supplescans (Figure 2D). Mucus plugs were defined as complete occlumental Table 2). These SARP 1 and SARP 2 scans were obtained
sion of a bronchus, irrespective of generation or size. When par2 to 9 years prior to the SARP 3 MDCT scans. Two radiologists at
allel to the scan plane, mucus plugs were recognized as tubular
the University of Wisconsin School of Medicine, Madison, center
densities with or without branching. When oriented obliquely or
read the 50 scans together to identify and score the mucus plugs.
perpendicularly to the scan plane, they were identified as oval
In a score-based analysis, we compared mucus scores assigned
or rounded opacities seen on sequential slices and differentiatto the first and second scans; mucus scores were unchanged in 7
ed from blood vessels by their continuity with patent portions
subjects (28%), increased in 10 subjects (40%), and decreased in
of the bronchial lumen and their position relative to adjacent
8 subjects (32%) over an average of 5.2 years (SD 2.5). We found
blood vessels (Supplemental Figure 1 and Supplemental Video
that 90% of subjects with a high mucus score (≥4) on the first
1). The segments of each lobe were systematically examined for
scan had a high score on the second scan (Figure 2G). In a segthe presence or absence of mucus plugs and given a score of 1 or
ment-based analysis, we compared individual lung segments in
0 accordingly (Supplemental Figure 8). The segment scores of
the first and second scans. Remarkably, 65% of lung segments
each lobe were summed to generate a total mucus score for both
that had a mucus plug on the first scan had a mucus plug in the
lungs, yielding an aggregate score ranging from 0 to 20. Periphsame segment on the second scan. We also found that 80% of
eral airways within 2 cm of the diaphragmatic pleura and costal
lung segments with no mucus plug on the first scan had no mucus
pleura were excluded from evaluation, as the small caliber of
plug in the same segment on the second scan (Figure 2, H and I).
these peripheral airways makes occlusion by mucus difficult to
Persistent presence or absence of mucus plugs from first to secascertain. Five radiologists with subspecialty training in thoracic
ond scan was seen with similar frequency across all bronchopulradiology reviewed the MDCT scans. Two radiologists were ranmonary segments (Supplemental Figure 2).
domly assigned to score each scan independently, and the scores
Airway mucus plugs usually occur in the absence of bronchiectasis.
of both raters were averaged to generate the CT mucus score of
At the same time that the radiologists scored the scans for mucus

Table 1. Characteristics of subjects with asthma across mucus score categories
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Figure 2. Development and distribution
of the CT mucus score in asthma patients
and healthy subjects. (A) Mucus plug with
branching (yellow arrow) seen in longitudinal
section is identified as a tubular opacification
(frontal plane). (B) Mucus plug (yellow arrow)
with extensive branching seen in longitudinal
section (transverse plane). (C) Mucus plug (yellow arrow) seen in cross-section is identified
as rounded opacification (transverse plane).
(D) Schematic representation showing how
MDCTs were evaluated to generate the mucus
score. Airways within the 2 cm peripheral zone
on MDCT (shown in red) or airways that were
partially occluded were excluded from assessment. Mucus plugs were defined as complete
occlusion of an airway. Each bronchopulmonary segment was assessed and scored for
the presence or absence of 1 or more mucus
plug(s), and the segment scores were summed
to generate the mucus score. (E) Segment
score in healthy patients and patients with
asthma. (F) Frequency distribution of segment
score in patients with asthma. The color code
above the x axis defines 3 mucus groups: green
indicates patients with a mucus score of 0
(zero mucus group); blue indicates patients
with mucus scores between 0.5 and 3.5 (low
mucus group); and orange indicates patients
with mucus scores of 4.0 or more (high mucus
group). (G) Sankey bar graph showing the
change in mucus score in 25 asthmatic subjects from SARP 1/2 to SARP 3. (H) Pie chart
of segments with mucus plugging on baseline
scan; 65% of these segments had mucus plugging on rescan. Pie chart of segments with no
mucus plugging on baseline scan; 79% of these
segments had no mucus plugging on rescan.
(I) MDCTs showing a mucus plug occluding the
airway (yellow arrow) of the right lower lobe in
2010 and a mucus plug occluding the same airway, visible more proximally (yellow arrow) and
branching into the adjacent airway, in 2013.
***P < 0.001, unequal variances t test.

plugging, they also systematically examined each of the 5 lung
lobes for the presence or absence of bronchiectasis, defined as a
bronchoarterial ratio of greater than 1.5. This approach generated
a mean bronchiectasis score ranging from 0 to 5 as well as a binary
outcome for presence or absence of bronchiectasis. We found that
only 20% of the subjects with asthma had bronchiectasis (Table
1 and Figure 3A) and that bronchiectasis tended to be more frequent in subjects with a high mucus score than in those with a
1000
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low or zero mucus score (Table 1) (P = 0.07). The prevalence of
bronchiectasis or mucus plugging did not differ among the 5 lung
lobes (Figure 3B), but the prevalence of mucus plugging was 4 to
5 times higher than that of bronchiectasis in any given lung lobe
(Figure 3B). Bronchiectasis was weakly but significantly associated with mucus plugging at a lobar level — mainly because most
lobes with bronchiectasis had mucus plugging (Figure 3C) — but
relatively few lobes with mucus plugging also had bronchiectasis
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Figure 3. Relationship between bronchiectasis and mucus plugging. (A) Frequency distribution of bronchiectasis score in patients with asthma. (B) Prevalence of bronchiectasis versus mucus plugging in each lung lobe. The prevalence of mucus plugging is 4 to 5 times higher than the prevalence of bronchiectasis in each lobe. There is no significant difference in prevalence of bronchiectasis or mucus plugging across individual lobes. (C) Mucus plugging is
present in 35% of lobes that have no bronchiectasis present and 58% of lobes that have bronchiectasis present (P = 0.001). (D) Bronchiectasis is present in
5% of lobes that have no mucus plugging present and only 12% of segments that have mucus plugging present (P = 0.001). There is a positive association
between mucus plugging and bronchiectasis, but mucus plugging usually occurs in the absence of bronchiectasis. (E) Pie charts illustrating the prevalence
of bronchiectasis in repeat CT scans in 25 patients. The data show that 83% of lung lobes with mucus plugs visible on the first scan had mucus plugging
visible on the second scan; in contrast, 99% of lung lobes with no mucus plugs visible in the first scan also had no mucus plugs visible on the second scan.

(Figure 3D). In an analysis of the 25 subjects with repeat MDCT
scans for comparison, there was a low prevalence of mucus plugging on initial CT scan (2 out of 25 subjects) and the prevalence
was unchanged in the second scan. In a lobe-based analysis, we
compared individual lung lobes in the first and second scans and
found that 83% of lung lobes (5/6 lobes) that showed bronchiectasis on the first scan showed bronchiectasis in the same lobe on the
second scan. We also found that 99% of lung lobes (118/119 lobes)
with no bronchiectasis on the first scan had no bronchiectasis in
the same lobe on the second scan (Figure 3E).
Airway mucus plugs strongly associate with measures of airflow
obstruction in asthma. To determine the association between airway mucus plugs and airflow obstruction in the subjects with asthma, we examined the relationship between the mucus score and
measures of airflow obstruction by spirometry. We found that the
mucus scores were inversely correlated with prebronchodilator
measures of FEV1 percentage of predicted volume (Spearman’s
rho = –0.51, P < 0.001), forced vital capacity (FVC) percentage
of predicted volume (Spearman’s rho = –0.32, P < 0.001), and
FEV1/FVC ratio of predicted volume (Spearman’s rho = –0.54, P <
0.001). These associations remained significant after controlling
for age, sex, and measures of airway wall thickness in regression

analyses (Table 2). The mean FEV1 was 25% lower in the high
mucus subgroup than in the zero mucus subgroup (Table 1 and
Figure 4A), and the values for the FVC and FEV1/FVC ratio were
also significantly decreased in the high mucus subgroup (Figure
4A). In addition, 66.7% of subjects with a prebronchodilator FEV1
of less than 60% of predicted volume had a high mucus score
compared with 19% of subjects with FEV1 60%–80% of predicted volume and 6.1% of subjects with FEV1 greater than 80% of
predicted volume (Figure 4B). The low FVC in subjects with high
mucus scores suggested air trapping in these subjects (14), and we
confirmed this in a subset of subjects (n = 43) who had undergone
body plethysmography as part of their baseline characterization
studies. Specifically, we found that the ratio of residual volume to
total lung capacity (RV/TLC) was also higher in the high mucus
group than in the low mucus group, indicating more air trapping in
the high mucus group (P = 0.04) (Supplemental Figure 3).
We next explored whether the strong association between
MDCT mucus scores and abnormal lung function is reflected in
abnormalities in other asthma outcomes. We found that, compared with the zero mucus group, the high mucus group had
higher asthma medication requirements, worse asthma control
test (ACT) scores, and were more frequently classified as having
jci.org   Volume 128   Number 3   March 2018
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Table 2. Relationship among mucus score, spirometry measures, and sputum eosinophils (adjusted for covariates)
Asthma outcomeA
FEV1, % of predicted volume
FVC, % of predicted volume
FEV1/FVC
Sputum eosinophils %B

Unadjusted

Model 1

Model 2

Model 3

Model 4

–2.2 (–2.8, –1.5)
R2 = 0.24, P < 0.001
–1.3 (–1.8 to –0.7)
R2 = 0.11, P < 0.001
–1.4 (–1.8 –1.0)
R2 = 0.26, P < 0.001
0.96 (0.7, 1.3)
R2 = 0.28, P < 0.001

–1.9 (–2.6, –1.3)
R2 = 0.28, P < 0.001
–0.9 (–1.5, –0.3)
R2 = 0.25, P = 0.002
–1.5 (–1.9, –1.1)
R2 = 0.29, P < 0.001
0.93 (0.6, 1.3)
R2 = 0.29, P < 0.001

–1.9 (–2.5, –1.2)
R2 = 0.34, P < 0.001
–0.9 (–1.4, –0.3)
R2 = 0.27, P = 0.003
–1.4 (–1.8, –1.0)
R2 = 0.34, P < 0.001
0.94 (0.6, 1.3)
R2 = 0.30, P < 0.001

–1.5 (–2.2, 0.8)
R2= 0.38, P < 0.001
–0.7 (–1.3, –0.04)
R2 = 0.29, P = 0.04
–1.3 (–1.7, –0.8)
R2 = 0.38, P < 0.001

–13 (–21.5, –4.8)
R2 = 0.41, P = 0.001
–6.5 (–14.4, 1.4)
R2 = 0.30, P = 0.1
–8.0 (–13, –2.7)
R2 = 0.41, P = 0.003

Linear regression model reports β coefficient (95% CI) for asthma outcomes. Predictor variable is mucus score ranging from 0 to 20. Model 1 adjusts for
the covariate of age at screening. Model 2 adjusts for the covariates of age and sex. Model 3 adjusts for the covariates of age, sex, and wall thickness
percentage. Model 4 adjusts for the covariates of age, sex, and an interaction term for mucus score minus wall thickness percentage. BSputum data was
missing in 40 patients.
A

severe asthma (Table 1 and Supplemental Methods). In addition,
the percentage of patients in the high mucus group who had experienced at least 1 asthma exacerbation in the previous year was
higher than in the zero mucus group, but this difference was not
statistically significant (Supplemental Table 3). Notably, only 2
asthma subjects in the cohort met criteria for a diagnosis of allergic bronchopulmonary aspergillosis (ABPA) (15), and both had
mucus scores in the low (0.5–3.5) range (Supplemental Table 3);
sensitivity to other molds and aeroallergens did not differ significantly among mucus groups (Supplemental Table 4).
Influence of airway mucus plugs on treatment responses to β adrenergic agonists and systemic corticosteroids. To explore whether airway
mucus plugs influence treatment responses, we first examined
responses to inhaled albuterol (540–720 mcg) using data from maximum bronchodilator reversibility testing (MBRT). Although there
was no significant difference in the absolute change in FEV1 following albuterol treatment among the 3 mucus groups (Figure 5A), we
found that the mean postbronchodilator FEV1 in the high mucus
group was 23% lower than in the zero mucus group (Figure 5B) and
that a persistently low FEV1 (FEV1 < 80% of predicted volume) following MBRT was common in subjects with a high mucus score, but
uncommon in subjects with a zero mucus score (Figure 5C).
We next examined responses to intramuscular triamcinolone acetonide (40 mg) using data from systemic corticosteroid
responsiveness testing (SCRT). Although there was no significant difference in the absolute change in FEV1 following corticosteroid treatment among the 3 mucus groups (Figure 5D), we
found that the mean poststeroid FEV1 was 20% lower in the high
mucus group than in the zero mucus group (Figure 5E). As with
the data for albuterol treatment, we noted that a persistently low
FEV1 following SCRT was common in subjects with a high mucus
score, but uncommon in subjects with a zero mucus score (Figure

Figure 4. Mucus plugging is associated with low lung function. (A)
Spirometric measures of lung function (FEV1, FVC, and FEV1/FVC) in the
subjects with a high mucus score were significantly lower than in subjects
with a low mucus score and subjects with a zero mucus score. (B) High
mucus plug scores were much more common in patients with severe
airflow obstruction. ***P < 0.001; **P < 0.01, Kruskal-Wallis test with
Dunn’s correction.
1002
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5F). In addition, we found that the CT mucus score was an independent predictor of residual abnormalities in FEV1 after systemic corticosteroid administration in logistic regression models
(Supplemental Figure 4).
Finally, we examined responses to combined treatment with
albuterol and systemic corticosteroid among the 3 mucus subgroups. Here, we found that the absolute change in FEV1 following
MBRT and SCRT was significantly higher in the high mucus group
than in the zero and low mucus groups (Figure 5G), but the mean
postbronchodilator/poststeroid FEV1 was still significantly lower
in the high mucus group than in the zero mucus group (Figure 5H).
Half of the subjects with high mucus scores had persistently low
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Figure 5. Persistent airflow obstruction is
seen in subjects with high mucus scores after
treatment with bronchodilators and steroids.
(A) The absolute change in FEV1 percentage of
predicted volume after bronchodilator treatment did not differ across mucus groups. (B)
The FEV1 percentage of predicted volume after
bronchodilator treatment was significantly
lower in the high mucus group than in the zero
mucus group. (C) Residual postbronchodilator
abnormalities in FEV1 (FEV1 < 80%) occur
more commonly in subjects with a high mucus
score than in those with a zero mucus score.
(D) The absolute change in FEV1 percentage of
predicted volume after steroid treatment did
not differ across mucus groups. (E) The FEV1
percentage of predicted volume after steroid
treatment was significantly lower in the high
and low mucus groups than in the zero mucus
group. (F) Residual poststeroid abnormalities in
FEV1 (FEV1 < 80%) occurred more commonly in
subjects with a high mucus score than in those
with a zero mucus score. (G) The absolute
change in FEV1 percentage of predicted volume
after bronchodilator and steroid treatment was
significantly higher in the high mucus group
than in the zero mucus group. (H) The FEV1
percentage of predicted volume after bronchodilator and steroid treatment was significantly
lower in the high mucus group than in the zero
mucus group. (I) Residual postbronchodilator
and poststeroid abnormalities in FEV1 (FEV1
< 80%) occurred more commonly in subjects
with a high mucus score than in those with a
zero mucus score. ***P < 0.001; **P < 0.01,
Kruskal-Wallis test with Dunn’s correction.

FEV1 following SCRT and MBRT, whereas only a small subgroup
of subjects with zero mucus scores had persistently low FEV1 (Figure 5I). Thus, aggressive treatment with β adrenergic agonists and
corticosteroids frequently does not normalize lung function in
subjects with airway mucus plugs, and additional treatments need
to be considered for these subjects.
Symptoms of CMH are neither sensitive nor specific for mucus
plugs. To determine whether subjects with asthma could have
mucus plugs without CMH symptoms, we examined the frequency of symptoms of CMH in the 3 mucus plug subgroups. Among
121 subjects who completed the cough and sputum questionnaire,
41 (34%) satisfied WHO criteria for CMH (cough and sputum production on most days for at least 3 months a year for at least 2 consecutive years) (16). We found that 16 (40%) subjects in the high
mucus group did not have symptoms of CMH (Table 1). Converse-

ly, we found that 18 (30%) subjects in the zero mucus group had
symptoms of CMH. Although the subgroup of subjects with CMH
did not have higher mucus scores than subjects without CMH, the
subjects with CMH were characterized by other clinical differences, such as older age, higher BMI, and evidence of more severe
asthma (Supplemental Table 5). Interestingly, subjects with CMH
did not differ from subjects without CMH in blood or sputum cell
differentials or in sputum cell gene expression of cytokines or
mucin genes (Supplemental Table 5).
Mucus plugging shown on MDCT scans is associated with airway
eosinophilia. To explore whether eosinophils play a pathophysiologic role in the formation of mucus plugs, we analyzed multiple
outcomes related to type 2 inflammation in blood and biospecimens in the 3 mucus subgroups. We found that eosinophils in
blood and sputum and nitric oxide levels in exhaled breath were
jci.org   Volume 128   Number 3   March 2018
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Figure 6. High mucus score is associated with markers of type 2 inflammation. (A) Sputum eosinophil percentage is significantly increased in
patients with a high mucus score and remains significantly increased in
patients with a high mucus score following treatment with intramuscular
steroid (triamcinolone acetonide). (B) The sputum eosinophil percentage
is significantly and positively associated with the mucus score. (C) Gene
expression for IL-13 is significantly increased in patients with a high mucus
score and remains significantly increased in patients with a high mucus
score following treatment with intramuscular steroid. (D) Gene expression for IL-5 is significantly increased in patients with a high mucus score
and remains significantly increased in patients with a high mucus score
following treatment with intramuscular steroid. (E) The MUC5AC/MUC5B
ratio is significantly increased in patients with high mucus scores. ***P <
0.001; **P < 0.01; *P < 0.05. P values were determined by Kruskal-Wallis
test with Dunn’s correction unless otherwise indicated.

significantly higher in the high mucus group than in the low and
zero mucus groups (Table 1 and Figure 6A). Among subjects with
high mucus scores, 71% had sputum eosinophilia (sputum eosinophils > 2%) and 66% had systemic eosinophilia (blood eosinophils
> 300 × 10–9/l). Airway mucus scores were positively and significantly associated with the sputum eosinophils (Spearman’s rho =
0.51, P < 0.001) (Figure 6B), and this relationship remained significant in linear regression models that controlled for age, sex, and
wall thickness percentage (Table 2). In addition, sputum eosinophils and fractional exhaled nitric oxide (FeNO) remained high in
many subjects with high mucus scores following systemic corticosteroid treatment, and the CT mucus score was an independent
predictor of residual sputum and elevated FeNO after systemic
corticosteroids in regression models (Supplemental Figure 5).
We next explored gene-expression outcomes related to type 2
inflammation and mucins in sputum cells from the 3 mucus sub1004
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groups. We found that gene expression for IL-13 and IL-5 in sputum cells was significantly higher in the high mucus group than in
the low and zero mucus groups and remained high following systemic corticosteroid treatment (Figure 6, C and D). In addition, we
found that the ratio of gene expression of MUC5AC to MUC5B in
sputum cells was significantly higher in the high mucus group than
in the low and zero mucus groups and normalized following systemic corticosteroid treatment (Figure 6E). The presteroid pattern
of a high expression of MUC5AC relative to MUC5B in the high
mucus group is typical of the activation effects of IL-13 on mucin
expression by airway epithelial cells (17).
EPO generates oxidants that crosslink cysteines and stiffen thiolated hydrogels. We have recently shown that neutrophil-driven
oxidation crosslinks cysteine-rich mucin polymers to stiffen airway mucus gels in cystic fibrosis (11), and we explored here whether eosinophil-driven oxidation might be a mechanism of mucus
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Figure 7. Eosinophil products are associated with mucus plugging. (A) The sputum eosinophil percentage is positively associated with sputum EPO levels.
(B) Sputum EPO is higher in the high mucus group (n = 32) than in the zero mucus group (n = 45) and healthy controls (n = 39). (C) Schematic representation of the cysteine-linking assay: 2 cysteines labeled with BODIPY FL fluoresce green as monomers but quench when oxidized to form a cystine dimer. (D)
Effect of EPO and H2O2 on cysteine crosslinking in the presence of chloride, bromide, or thiocyanate. Cysteines do not undergo significant crosslinking with
EPO and H2O2 in the presence of chloride, but cysteines exposed to EPO and H2O2 in the presence of bromide, and especially thiocyanate, undergo much
more oxidation and crosslinking. RFU, relative fluorescent units. (E) Effect of HOSCN, the product of EPO-catalyzed reaction of H2O2 and thiocyanate, on
the viscoelastic properties of a thiolated hydrogel measured by rheology. A large increase in the elastic modulus (G′) of the hydrogel was seen following
exposure of the hydrogel to EPO with H2O2 and KSCN. There was no significant increase in G′ in the hydrogel in the absence of EPO. (F) Conceptual model
for how type 2 inflammation promotes airway mucus plug formation in asthma. IL-13 increases thiocyanate transfer into the airway lumen. Once in the
airway lumen, it is oxidized by H2O2 to form HOSCN, a reaction catalyzed by EPO. HOSCN targets cysteine thiol groups in secreted mucin polymers to generate covalent disulfide mucin crosslinks. Crosslinked mucins have a high elasticity that decreases their clearance by the mucociliary escalator and results in
mucus plug formation. The data are presented as mean ± SD of 3 replicates in D and 4 replicates in E. *P < 0.05; **P < 0.01; †P < 0.01; ‡P < 0.001. P value
was determined by ANOVA with Bonferroni’s correction.

plug formation in asthma. The activity of EPO can generate
products that target thiol groups as a cytotoxic mechanism (10),
and we considered the possibility that EPO-generated products
oxidize the thiol groups of cysteine residues in mucin polymers
to cause mucus plugs to form. As a first step, we measured EPO
in sputum from the zero and high mucus subgroups and healthy
controls. We found a positive correlation between sputum EPO
levels and sputum eosinophils (Spearman’s rho = 0.59, P < 0.001)
(Figure 7A) and also found that EPO levels in the high mucus plug
group were markedly higher than in the zero mucus group and
in healthy controls (Figure 7B). We next tested the effect of EPO
activity on cysteine crosslinking using 2 model systems of the

airway mucus gel. The first model was a boron-dipyrromethene–
labeled (BODIPY-labeled) cysteine reagent that quenches when
cysteine forms its oxidized disulfide product (cystine) (Figure
7C). The second model system was a synthetic thiolated hyaluronan reagent that forms a hydrogel and increases its elasticity when oxidized (18). EPO catalyzes the oxidation of chloride,
bromide, and thiocyanate by H2O2 to hypochlorous acid (HOCl),
hypobromous acid (HOBr), and HOSCN, respectively. Specificity
constants indicate that thiocyanate is a major substrate for EPO,
and HOSCN is known to be a more thiol-specific oxidant than
HOBr or HOCl (10). To test whether EPO generates HOSCN that
catalyzes conversion of cysteine to its oxidized disulfide product
jci.org   Volume 128   Number 3   March 2018
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(cystine), we exposed BODIPY-labeled cysteine to EPO in the
presence of H2O2 and either chloride (NaCl), bromide (NaBr),
or thiocyanate (KSCN). We found no significant cystine dimer
formation when BODIPY-labeled cysteine was exposed to EPO,
H2O2, and chloride, but dimer formation was significantly greater
when the BODIPY-labeled cysteine was exposed to EPO, H2O2,
and bromide and was greatest when the BODIPY-labeled cysteine was exposed to EPO, H2O2, and thiocyanate (Figure 7D).
Thus, HOBr and HOSCN can oxidize cysteines, but HOSCN
is more potent and HOCl has no effect in this system. We next
tested to determine whether HOSCN can crosslink the thiolated
hyaluronan reagent. Here, we used a cone and plate rheometer
to measure changes in the elasticity of the hydrogel under different conditions. We found that the combination of EPO, H2O2,
and thiocyanate markedly increased the elasticity of the thiolated
hyaluronan gel and that EPO was required for this effect (Figure
7E). Thus, HOSCN can convert a thiolated hydrogel from a liquid
form to a solid form, leading us to propose that HOSCN is an oxidant product of EPO activity that may mediate mucus plug formation in asthma (Figure 7F).
Nearly 60% of the subjects in the high mucus subgroup had
reported an asthma exacerbation in the previous year, but nearly 50% of the zero mucus group had also experienced an asthma
exacerbation in that time frame. The 20% increase in exacerbations in the high versus zero mucus groups did not reach statistical significance in our cohort, and larger studies than ours will
be needed to more fully explore the relationship between airway
mucus plugs and exacerbations in severe asthma.

Discussion

Among the asthmatic subjects we studied, 66% had physiologic
evidence of airflow obstruction and 27% had severe obstruction. Using a method of quantifying mucus plugs based on visual assessment of MDCT scans by experienced chest radiologists,
we found a strong inverse relationship between the MDCT mucus
score and FEV1 values. We also found that the majority of subjects
with severe obstruction had at least 4 bronchial subsegments with
1 or more airways completely occluded with mucus. Some of these
subjects had mucus plugs in more than half of their bronchial subsegments. Although strong associations do not prove causality,
we propose that the association between mucus plugs and airflow
obstruction in these subjects with asthma is causal because mucus
plugs that completely occlude subsegmental airways will cause
regional airflow obstruction at a minimum and more widespread
airflow limitation when present in multiple bronchopulmonary
segments. Indeed, we found that subjects with high mucus scores
had air trapping, as evidenced by low FVC and high RV. Air trapping is recognized as a prominent characteristic of severe forms of
asthma, but the mechanisms have not been well understood (14).
The mucus plugs we identify here represent a plausible mechanism of air trapping in at least some of the subjects who have this
physiologic abnormality.
Although the mucus plugs were heterogeneously distributed in the 20 bronchopulmonary segments among subjects, we
found that they tended to be found in the same bronchopulmonary segment within individual subjects over long periods of time.
The mechanism of this susceptibility to mucus plug formation
1006
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in specific airways is not anatomical because bronchiectasis was
an uncommon finding in our patients and mucus plugs usually
occurred in the absence of bronchiectasis. We consider it unlikely
that the same mucus plug is long lived for years in an airway and
more likely that mucus plugs repeatedly form and reform in susceptible bronchopulmonary segments. We speculate that these
segments are susceptible to mucus plugging because they have
heightened type 2 inflammation based on associations we found
between high mucus plug scores and increased sputum measures
of eosinophils and type 2 cytokines.
The protocol followed by participants in SARP included a
maximal bronchodilator reversibility test and a systemic corticosteroid response test. Data from these tests allowed us to comprehensively assess the effect of mucus plugs on treatment responses
to inhaled albuterol and systemic triamcinolone. We discovered
that subjects in the high mucus subgroup who had marked reduction in FEV1 and FVC pretreatment frequently did not normalize
their FEV1 or FVC after treatment. One possibility is that mucus
plugs are not substantially affected by these treatments and that
specific mucoactive drugs will need to be used in these subjects in
order to normalize their lung function. The CT mucus score that
we describe here will be invaluable in identifying subjects for precision clinical trials of this approach. In this regard, it is important
that we discovered that symptoms of CMH are neither sensitive
nor specific for the mucus plug phenotype we uncovered here, perhaps because the mucus plugs occur in subsegmental airways that
lack large numbers of cough receptors (19–21). We also show that
the clinical and airway inflammation features of the CMH phenotype are different from the features of the mucus plug phenotype.
Thus, not all mucus phenotypes in asthma are the same, and we
demonstrate the unique ability of MDCT lung imaging to identify
patients with a mucus plug phenotype.
Airway mucus in health is normally a lightly crosslinked gel
that does not form plugs (22, 23), and it is puzzling why mucus
plugs were so common in our subjects. Cellular and molecular
analyses of airway biospecimens from subjects with mucus plugs
and controls provided valuable clues about the mechanism of
mucus plug formation. The main clue came from analysis of sputum leukocytes in which we found that subjects with mucus plugs
had marked sputum eosinophilia. They also had marked increases in sputum cell gene expression for type 2 cytokines, such as
IL-5 and IL-13, and a relative increase in MUC5AC gene expression over MUC5B. This latter finding is relevant because cysteine
domains are more prevalent in MUC5AC than in MUC5B (24), and
we have previously shown that neutrophil-driven oxidation in the
airways in cystic fibrosis can crosslink cysteine-rich mucin polymers to stiffen the mucus gel (11). In our studies, we found strong
evidence that eosinophil-driven oxidation mediates mucus plug
formation in asthma. First, we found that EPO levels were high
in subjects with mucus plugs and that EPO showed activities in
model systems of the airway mucus gel that promoted increased
elasticity of the gels. Specifically, we found that EPO catalyzed
reactions of H2O2 with bromide and thiocyanate to generate oxidants (HOBr and HOSCN, respectively) that could convert cysteines to their oxidized disulfide products (cystines). We also found
that HOSCN could oxidize a thiolated hydrogel to convert it from
a liquid form to a solid form. HOSCN could be expected to form in
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the lumen of asthmatic airways because of the pleotropic effects
of type 2 cytokines, which included effects that caused eosinophil
accumulation (23), hydrogen peroxide production (25), and pendrin upregulation (26). Pendrin is relevant because it mediates the
exchange of thiocyanate across airway epithelial cells (27). Taken
together, our data lead us to propose that mucus plugs form in the
airways of patients with asthma because of multiple consequences
of airway type 2 inflammation that lead to mucin-eosinophil interactions that promote mucus plugs (Figure 7F).
In summary, our data provide strong evidence that airway
mucus plugs are common in chronic severe asthma, persist over
time, and contribute to mechanisms of chronic airflow obstruction.
We also provide data to implicate EPO as a key mediator in generating thiol-specific oxidants that oxidize mucins to cause mucus
plugs to form. We propose that the detection of mucus plugs in the
lung using MDCT lung scans can serve as a biomarker of disease
severity in the airways of patients with asthma and can be indicative of outcome for clinical trials that could determine whether mucolytics or inhibitors of type 2 inflammation can decrease
mucus plugs to improve airflow in chronic severe asthma.

Methods

Subjects. Adult asthma subjects were recruited as part of the SARP 3
cohort. The SARP 3 protocol includes 3 baseline visits in which asthma
subjects undergo detailed characterization, including sputum questionnaires, MBRT, a systemic corticosteroid responsiveness test, and
an optional MDCT scan of the lungs (Supplemental Figure 6). Data
reported here are from subjects that had MDCT scans as part of their
baseline characterization. CT was not repeated after steroid injection.
Healthy subjects for MDCT scans were recruited at a single center
(Washington University), and subjects for sputum cell analyses were
recruited from all SARP 3 centers (Supplemental Table 1). Twentyfive asthma subjects who had MDCT scans as part of the SARP 3 protocol also had MDCT scans available from their participation in SARP
1 or SARP 2 protocols. These subjects were enrolled at 3 sites: University of Pittsburgh, University of Wisconsin, and Washington University (Supplemental Table 2). Forty-three asthma subjects who had
MDCT scans as part of the SARP 3 protocol also had plethysmography
performed. These subjects were enrolled at the University of Wisconsin (Supplemental Table 1).
Sputum and cough questions. Questionnaires were completed by
asthma subjects at study entry. CMH was defined using the ATS/
WHO definition of chronic bronchitis, which assesses chronic cough
and sputum production in the preceding 2 years (16). The specific
question used was the following: Have you had cough and sputum
production on most days for at least 3 months a year for at least 2
consecutive years?
MBRT. Subjects were asked to hold their bronchodilator medications prior to spirometry testing. Following baseline spirometry, 4
puffs of albuterol (360 mcg) were administered. Spirometry was then
repeated 15 minutes later. If the change in FEV1 from the spirometry
maneuver performed after 4 puffs was greater than 5%, an additional
2 puffs of albuterol (180 mcg) were then administered and spirometry
was repeated again 15 minutes later. If the change in FEV1 after 6 puffs
was greater than 5%, an additional 2 puffs of albuterol were administered with repeat spirometry after an additional 15 minutes. If the
change was less than 5% after 4 or 6 puffs of albuterol, the procedure
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was stopped and the last maneuver was taken to be the highest achievable measure. No more than 8 puffs of albuterol were administered as
part of the MBRT procedure. MBRT was measured on baseline visits 2
and 3 (Supplemental Figure 6).
SCRT. Subjects were given an intramuscular injection of triamcinolone acetonide (40 mg) following complete characterization on visit
2. Repeat characterization after steroid injection (excluding MDCT)
was carried out on visit 3 (2 to 4 weeks later) (Supplemental Figure 6).
MDCT protocol and analysis. Details about the MDCT parameters are provided in Supplemental Tables 6 and 7. A standard window
width of 1200 HU and level of 600 HU were used for visual bronchial wall evaluation (28). Radiologists were blinded to the clinical
characteristics of the subjects. Quantitative measures of airway wall
thickness and lumen area were generated using Apollo 1.2 (VIDA
Diagnostics) (Supplemental Figure 7) and further described in the
Supplemental Methods.
Sputum induction, cell counts, and gene expression. Sputum induction was performed on visits 2 and 3 (Supplemental Figure 6). For safety, induced sputum was only collected from subjects whose FEV1 was
more than 50% of predicted volume after albuterol pretreatment (360
ug). Total and differential cell counts and sputum cell gene expression
were quantified at a centralized laboratory using methods previously
described (29–31). The primers and probes used for measurement of
gene expression are provided in Supplemental Table 8.
EPO assay. Human EPO was measured by sandwich ELISA in
supernatant collected by sputum induction methods adopted from
the NHLBI Asthma Clinical Research Network (32). Samples were
diluted 1:50 in assay diluent, per manufacturer-recommended protocols (Diagnostic Development). The detection limit of the assay is
less than 0.2 ng/ml.
Cysteine crosslinking assay. To explore cystine formation generated by EPO with H2O2 in the presence of chloride, bromide, or thiocyanate, BODIPY FL L-cysteine was generated from 800 mM BODIPY
FL L-cystine (Thermo Fisher Scientific) in Tyrode’s Salts by reduction
with one-quarter volume packed TCEP-Gel (Thermo Fisher Scientific) for 1 hour at 25°C. The reaction yielded an 8- to 10-fold increase in
fluorescence at 490 nm/520 nm excitation/emission (Ex/Em). This
reagent was diluted in 100 μl Tyrode’s Salts to 4 μM with and without
PMA (100 ng) in 96-well round-bottom nontreated black polystyrene
plates (Corning Costar). The decrease in fluorescence at 490 nm/520
nm Ex/Em was monitored over 90 minutes at 37°C on a Synergy H1
plate reader (BioTek Instruments) with the addition of EPO with H2O2
and a (pseudo)halide. The plates were sealed with optical adhesive
film (Applied Biosystems) to prevent evaporation. The quenching of
BODIPY fluorescence by eosinophil stimulation was shown to return
to baseline values by the addition of DTT to the wells at the end of
incubation, indicating that this effect was due to reformation of cystine and not destruction or bleaching of the fluorophore.
Thiolated hydrogel. HOSCN, the product of the EPO-catalyzed
reaction of H2O2 with potassium thiocyanate (KSCN), was examined
for its ability to increase the elasticity of thiolated hyaluronic acid.
KSCN (2 mM) and H2O2 (2 mM) were incubated for 15 minutes at 25°C
with or without EPO (6 nM) in a 0.5% solution of thiolated hyaluronic
acid/phosphate buffer pH 7.4 (Glycosil, Ascendance Bio). The elastic
moduli (G′) for the solutions were then measured on a cone and plate
rheometer (TA Instruments) oscillating at 1 Hz and 5% strain. The gel
solution without reactants was also assessed for background elasticity.
jci.org   Volume 128   Number 3   March 2018
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Statistics. Agreement between raters was estimated using the ICC
calculated with a 1-way random effects ANOVA model. Within-rater
agreement was calculated using a random subset of 14 scans. Categorical variables are presented as frequencies with percentages and were
evaluated using the χ2 test. Continuous variables are presented as mean
± 1 SD or medians with quartiles. Box-and-whisker plots were prepared
showing the median (marked by a horizontal line), 25% and 75% quartiles (box), and 1.5× interquartile range (IQR) (whiskers). Data points
outside 1.5 IQR are plotted as outliers. One-way ANOVA was used
for multiple group comparison, followed by Bonferroni’s correction.
Kruskal-Wallis 1-way ANOVA was used for nonparametric multiple
group comparison. Correlation between variables was evaluated using
Spearman’s correlation. Multivariable analyses were calculated using
linear and logistic regression models (with 95% CIs). Two-sided P values of less than 0.05 were considered statistically significant. Statistical analysis was carried out using Stata 13.1 (StataCorp).
Study approval. Written informed consent approved by each center’s institutional review board was received from participants prior to
inclusion in the study. Study procedures and sample collection were
carried out using standardized protocols approved by each center’s
institutional review board.
Data availability. Data are available on request from the authors.
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